Tucatinib, HER2 inhibitor, with Herceptin and Capecitabine associated with improved PFS,(HR: 0.54 p<0.00001), compared with Herceptin+Cape, in metastatic HER2+ disease. Also, improved PFS in brain-mets subgroup and OS. Presentation at #SABCS19 #bcsm
Impressive findings, as per PR, for Tucatinib in locally advanced or metastatic HER2+ breast cancer, in combination w/ other drugs (trastuzumab and capecitabine), with or w/out known brain mets. ↑ #PFS #OS - #bcsm #HER2CLIMB
⁩ with +++ Results from Tucatinib (HER2-specific kinase inhibitor) in Metastatic HER2+ Breast Cancer, post HER2-targeting TX ⁦⁩ ⁦⁩ ⁦⁩ ⁦⁩ ⁦
There has been a lot of terrific news and research in the HER2 space lately. Great to see it.